Goldman Sachs Group Inc Anavex Life Sciences Corp. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 662,102 shares of AVXL stock, worth $5.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
662,102
Previous 457,163 44.83%
Holding current value
$5.71 Million
Previous $1.93 Million 94.92%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$4.11 - $7.04 $842,299 - $1.44 Million
204,939 Added 44.83%
662,102 $3.76 Million
Q2 2024

Aug 13, 2024
SELL
$3.39 - $5.02 $261,196 - $386,785
-77,049 Reduced 14.42%
457,163 $1.93 Million
Q1 2024

May 15, 2024
BUY
$4.55 - $6.75 $1.22 Million - $1.81 Million
267,639 Added 100.4%
534,212 $2.72 Million
Q4 2023

Feb 13, 2024
BUY
$5.04 - $9.95 $229,602 - $453,282
45,556 Added 20.61%
266,573 $2.48 Million
Q3 2023

May 14, 2024
SELL
$6.55 - $9.37 $298,391 - $426,859
-45,556 Reduced 17.09%
221,017 $1.45 Million
Q3 2023

Nov 14, 2023
SELL
$6.55 - $9.37 $649,648 - $929,344
-99,183 Reduced 30.98%
221,017 $1.45 Million
Q2 2023

May 14, 2024
SELL
$7.66 - $9.5 $2.69 Million - $3.34 Million
-351,612 Reduced 52.34%
320,200 $2.6 Million
Q2 2023

Aug 14, 2023
SELL
$7.66 - $9.5 $2.69 Million - $3.34 Million
-351,612 Reduced 52.34%
320,200 $2.6 Million
Q1 2023

May 14, 2024
SELL
$8.32 - $11.75 $258,693 - $365,342
-31,093 Reduced 4.42%
671,812 $5.76 Million
Q1 2023

May 11, 2023
SELL
$8.32 - $11.75 $258,693 - $365,342
-31,093 Reduced 4.42%
671,812 $5.76 Million
Q4 2022

May 14, 2024
BUY
$7.65 - $14.43 $3.01 Million - $5.68 Million
393,592 Added 127.25%
702,905 $6.51 Million
Q4 2022

Feb 13, 2023
BUY
$7.65 - $14.43 $3.01 Million - $5.68 Million
393,592 Added 127.25%
702,905 $6.51 Million
Q3 2022

May 14, 2024
SELL
$8.9 - $12.86 $432,068 - $624,314
-48,547 Reduced 13.57%
309,313 $3.19 Million
Q3 2022

Nov 10, 2022
SELL
$8.9 - $12.86 $432,068 - $624,314
-48,547 Reduced 13.57%
309,313 $3.19 Million
Q2 2022

May 14, 2024
BUY
$7.31 - $12.84 $667,307 - $1.17 Million
91,287 Added 34.24%
357,860 $3.58 Million
Q2 2022

Aug 15, 2022
SELL
$7.31 - $12.84 $591,408 - $1.04 Million
-80,904 Reduced 18.44%
357,860 $3.58 Million
Q1 2022

May 16, 2022
BUY
$9.74 - $17.69 $567,832 - $1.03 Million
58,299 Added 15.32%
438,764 $5.4 Million
Q4 2021

Feb 14, 2022
BUY
$16.88 - $23.31 $4.6 Million - $6.36 Million
272,791 Added 253.35%
380,465 $6.6 Million
Q3 2021

Nov 10, 2021
BUY
$16.82 - $25.75 $1.81 Million - $2.77 Million
107,674 New
107,674 $1.93 Million

Others Institutions Holding AVXL

# of Institutions
155
Shares Held
27.3M
Call Options Held
515K
Put Options Held
838K
View Full List

About ANAVEX LIFE SCIENCES CORP.

AVXL Quotes by TradingView
  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $673M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email